Stockreport

TRACON Pharmaceuticals Provides Update on Phase 1/2 Trial of TRC253 in Patients with Metastatic Castrate Resistant Prostate Cancer

TRACON PHARMS INC  (TCON) 
Last tracon pharms inc earnings: 2/27 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: traconpharma.com
PDF Phase 1 Data Published in ASCO Proceedings Determined the Recommended Phase 2 Dose Additional Cohort of Patients with a Specific Androgen Receptor Point Mutation Adde [Read more]